Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Aug 14, 2023

BUY
$2.48 - $5.22 $48,960 - $103,053
19,742 New
19,742 $91,000
Q1 2023

May 15, 2023

BUY
$2.48 - $5.22 $48,960 - $103,053
19,742 New
19,742 $91,000
Q3 2022

Nov 14, 2022

BUY
$3.09 - $7.46 $185 - $447
60 Added 0.06%
104,293 $329,000
Q1 2022

May 16, 2022

BUY
$5.07 - $7.2 $50 - $72
10 Added 0.01%
104,233 $626,000
Q3 2021

Nov 15, 2021

SELL
$13.4 - $16.3 $27,751 - $33,757
-2,071 Reduced 1.95%
104,223 $1.44 Million
Q1 2021

May 14, 2021

BUY
$14.52 - $23.53 $145,069 - $235,088
9,991 Added 10.37%
106,294 $1.89 Million
Q4 2020

Feb 17, 2021

BUY
$10.14 - $15.19 $40,205 - $60,228
3,965 Added 4.29%
96,303 $1.38 Million
Q3 2020

Nov 13, 2020

BUY
$9.57 - $21.32 $9 - $21
1 Added 0.0%
92,338 $933,000
Q1 2020

May 15, 2020

SELL
$9.03 - $19.72 $63,209 - $138,040
-7,000 Reduced 7.05%
92,337 $660,000
Q3 2019

Nov 14, 2019

SELL
$14.55 - $20.56 $20,457 - $28,907
-1,406 Reduced 1.4%
99,337 $1.62 Million
Q2 2019

Aug 13, 2019

BUY
$15.0 - $19.62 $37,125 - $48,559
2,475 Added 2.52%
100,743 $1.58 Million
Q4 2018

Feb 14, 2019

BUY
$10.72 - $16.73 $48,240 - $75,285
4,500 Added 4.8%
98,268 $1.1 Million
Q3 2018

Nov 14, 2018

SELL
$17.73 - $26.69 $184,267 - $277,389
-10,393 Reduced 9.98%
93,768 $2.29 Million
Q2 2018

Aug 14, 2018

SELL
$10.79 - $24.44 $5,783 - $13,099
-536 Reduced 0.51%
104,161 $1.89 Million
Q1 2018

May 15, 2018

BUY
$9.0 - $20.16 $27,225 - $60,984
3,025 Added 2.98%
104,697 $1.17 Million
Q4 2017

Feb 13, 2018

BUY
$13.26 - $22.86 $1.35 Million - $2.32 Million
101,672
101,672 $1.98 Million

Others Institutions Holding OMER

About OMEROS CORP


  • Ticker OMER
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,730,000
  • Market Cap $585M
  • Description
  • Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers related to dysfunction of the immune system, and addictive and compulsive disorders. The company's clinical program...
More about OMER
Track This Portfolio

Track United Capital Financial Advisers, LLC Portfolio

Follow United Capital Financial Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of United Capital Financial Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on United Capital Financial Advisers, LLC with notifications on news.